Form 4: Elanco Animal Health Executive David S. Kinard Reports Stock Transactions

Executive Vice President David S. Kinard reports acquisition of restricted stock units and stock options, as well as disposition of shares to cover tax obligations.

Summary

• On March 1, 2024, David S. Kinard, an Executive Vice President at Elanco Animal Health Inc., was granted 15,596 restricted stock units.
• These units vest in three equal installments on March 1, 2025, March 1, 2026, and March 1, 2027.
• On the same day, Kinard also acquired 34,014 stock options, also vesting in three equal installments on the same dates.
• Kinard disposed of 5,731 shares of common stock at a price of $16.03 to cover his tax liability related to the vesting of previously awarded restricted stock units.
• Following these transactions, Kinard directly owns 149,646 shares of Elanco Animal Health Inc. common stock and 34,014 stock options.

Sentiment

Score: 5

Explanation: The document reflects standard executive compensation practices and tax-related transactions, indicating a neutral sentiment.

Positives

• The grant of restricted stock units and stock options to an executive aligns their interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Future Outlook

The vesting schedule of the restricted stock units and stock options extends to March 1, 2027, indicating a long-term incentive structure for the executive.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions have a minor impact on shareholders, reflecting standard executive compensation practices.
• The vesting schedule incentivizes the executive to contribute to the company's long-term success, potentially benefiting all stakeholders.

Key Dates